Wednesday, May 12, 2021 11:16:07 AM
LOBE Presenting At Virtual Investor Conference Friday!
Lobe Sciences Invites You to Join Us at the Q2 Virtual Investor Summit
2021-05-12 05:04 PT - News Release
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - Lobe Sciences (CSE: LOBE) today announced that Philip Young, CEO and Director, will be attending the Q2 Virtual Investor Summit.
Event Q2 Investor Summit
Date May 17-18th, 2021
Presentation May 18th at 10:15 AM ET
Location Register Here
About Lobe Sciences
Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information:
Lobe Sciences
Philip Young CEO & Director
(949) 505-5623
info@lobesciences.com
Lobe Sciences Invites You to Join Us at the Q2 Virtual Investor Summit
2021-05-12 05:04 PT - News Release
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - Lobe Sciences (CSE: LOBE) today announced that Philip Young, CEO and Director, will be attending the Q2 Virtual Investor Summit.
Event Q2 Investor Summit
Date May 17-18th, 2021
Presentation May 18th at 10:15 AM ET
Location Register Here
About Lobe Sciences
Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information:
Lobe Sciences
Philip Young CEO & Director
(949) 505-5623
info@lobesciences.com
Recent LOBEF News
- Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York • ACCESS Newswire • 05/07/2026 12:00:00 AM
- Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress • ACCESS Newswire • 05/06/2026 10:00:00 AM
- Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders • ACCESS Newswire • 04/23/2026 12:00:00 PM
- Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services • ACCESS Newswire • 04/21/2026 10:00:00 AM
- Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update • ACCESS Newswire • 04/20/2026 10:00:00 AM
- Lobe Sciences Ltd. Announces Non-Brokered Private Placement • ACCESS Newswire • 04/11/2026 12:00:00 AM
- Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update • ACCESS Newswire • 03/25/2026 12:20:00 PM
- Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer • ACCESS Newswire • 03/09/2026 04:00:00 AM
- Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences • ACCESS Newswire • 03/05/2026 12:40:00 PM
- Lobe Sciences Reports First Quarter 2026 Results and Highlights • ACCESS Newswire • 02/03/2026 12:00:00 PM
- Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors • ACCESS Newswire • 01/13/2026 12:00:00 PM
- Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy • ACCESS Newswire • 01/08/2026 01:55:00 PM
- Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition • ACCESS Newswire • 01/06/2026 11:00:00 AM
